IceCure Medical (ICCM) Registration filing summary

Company overview and business model

• Commercial-stage medical device company specializing in cryoablation systems using liquid nitrogen for tumor treatment, offering minimally invasive alternatives to surgery for various tumor types including breast, lung, kidney, and bone.

• Lead product, ProSense system, is FDA-authorized for local treatment of low-risk breast cancer in women aged 70+ with adjuvant endocrine therapy.

• Operations are based in Israel with subsidiaries in the US, Hong Kong, and China; listed on Nasdaq and Tel Aviv Stock Exchange.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were $8.9 million; pro forma as adjusted for recent offerings, cash would be $21.2 million.

• Shareholders' equity as of December 31, 2025, was $9.1 million, increasing to $21.4 million pro forma as adjusted.

• March 2026 offering raised gross proceeds of $4.0 million, with potential for an additional $8.8 million if all warrants are exercised.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling shareholders; proceeds from warrant exercises will be used for working capital and general corporate purposes.